Parameter
| Biomarker | miR-340-5p | Full name | MicroRNA-340-5p | Molecular Type | Nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Predict response to therapy and prognosis |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Serum (miRNA sequencing, RT-qPCR) | ||
| Pathobiological Mechanisms | Regulation of PD-L1 involvement in immune evasion, low levels of miR-340-5p associated with reduced efficacy of pembrolizumab | ||||
| Clinical Availability Status | Research validation phase: Cell line and small-sample cohort validation is valid, requiring multicenter large-sample trials and standardized testing | ||||
| Notes and Dynamics | It is expected to guide immunotherapy regimens, focusing on optimizing detection sensitivity and exploring combined biomarkers. | ||||